Johnson & Johnson (JNJ) Financial News - Drugmakers Seek End or Changes to U.S. Medication Naming Rules
Johnson & Johnson (JNJ)
Drugmakers Seek End or Changes to U.S. Medication Naming Rules
2011-08-16 03:04:34Quote: Johnson & Johnson (JNJ)GlaxoSmithKline Plc (GSK)post on Philly.com. Pennsylvania. â€œWithout this set of eyes, there is little doubt that the number of serious errors could be far greater.â€ PhRMA agrees with Cohen that industry and other stakeholders should meet with the FDA to improve the process, said Jeffrey Francer, the groupâ€™s assistant general counsel. Those parties should determine how often name confusion contributes to medical errors and make the agencyâ€™s review process more transparent, moving decisions earlier to prevent approval delays, Francer said today in an interview. Revising Packaging The FDA said in June that J&J and Glaxo should revise packaging for drugs that have similar names after mix-ups sent at least five patients to the hospital for taking the wrong medication. New Brunswick, New Jersey-based J&J, and Requip, a medicine for Parkinsonâ€™s disease and restless-leg disorder made by London-based Glaxo. AstraZeneca Plc (AZN)Dexilant. Washingtonaedney@bloomberg.net. firstname.lastname@example.org. ...
Open whole article (external link)
Other Financial and Stock Market News concerning Johnson & Johnson
Warren Buffett's Top 6 High-Yield Stocks: Beating the Broader Market So Far in 2011 (2011-08-15 01:06:47)
Johnson & Johnson Earnings Cheat Sheet: Margins Shrink For Fifth Straight Quarter as Profit Falls (2011-07-19 08:56:02)